India Poised to Offer Cheaper Weight Loss Drugs After Patent Expiration

India is on the brink of a significant shift in the weight loss medication market as the patent for semaglutide, the active ingredient in the popular drug Ozempic, is set to expire in March 2024. This could lead to a dramatic price drop of up to 90% for weight loss medications in India, potentially making them more accessible to millions. Analysts project that the semaglutide market could grow to $1 billion, with major Indian pharmaceutical companies like Dr. Reddy’s and Cipla preparing to launch generic versions. This development is crucial as India faces a growing obesity crisis, with projections indicating that 450 million adults could be overweight by 2050. Consumers should stay informed about the availability and pricing of these new medications as they become available.

Key Details: • Patent for semaglutide expires in March 2024, leading to potential price drops. • Generic versions expected to reduce costs to approximately $77 per month within a year. • Major companies like Dr. Reddy’s and Cipla are preparing to manufacture these medications. • Projected market growth for semaglutide could reach $1 billion. • Stay updated on new medication availability and pricing in pharmacies.